BioPharma Dive February 13, 2025
Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million.
A startup focused on brain drugs officially launched Thursday, backed by $94 million from a group of investors that includes one of the world’s largest banks and the parent company of Ozempic maker Novo Nordisk.
Boston-based Newleos Therapeutics hopes to develop new treatments for a broad range of mental health conditions. The biotechnology company’s pipeline, which it licensed from Swiss pharmaceutical giant Roche, has four drugs in human testing for conditions like generalized anxiety disorder, substance use disorder and cognitive impairment.
The drugs are designed to regulate different molecules and proteins involved in brain cell communication. The most advanced has completed Phase 1...
Today's Sponsors
Today's Sponsor